A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

Table 3 Summary of additional deterministic scenario analyses

Scenario	Incremental LYs	Incremental QALYs	Incremental costs	ICER
Deterministic base case	0.86	0.80	SGD 540	SGD 677/QALY
Discount rate (0%)	1.63	1.41	SGD 4842	SGD 3446/QALY
Discount rate (5%)	0.59	0.58	SGD 32	SGD 55/QALY
Time horizon 30 years	0.69	0.68	− SGD 2888	Dominant
Time horizon 50 years	0.95	0.86	SGD 2726	SGD 3168/QALY
OS HR approach	0.72	0.70	SGD 4605	SGD 6593/QALY
OS combined fit alternate curve	0.64	0.63	− SGD 16,250	Dominant
DoT KM individual treatments	0.86	0.80	− SGD 31,454	Dominant
DoT KM by treatment arm	0.86	0.80	− SGD 33,187	Dominant
DoT KM then extrapolated by response	0.86	0.80	SGD 13,876	SGD 17,370/QALY
DoR alternative curve	0.86	0.70	SGD 49,472	SGD 70,758/QALY
Societal perspective	0.86	0.80	− SGD 27,960	Dominant
Age-adjusted utilities: regression equation	0.86	0.73	SGD 540	SGD 739/QALY
Age-adjusted utilities: Gen pop age category	0.86	0.81	SGD 540	SGD 669/QALY
Single comparator: ECP	0.70	0.68	− SGD 82,391	Dominant
Single comparator: MMF	0.72	0.70	SGD 63,741	SGD 91,199/QALY
Single comparator: MTX	1.02	0.91	SGD 76,198	SGD 83,448/QALY
BAT distribution based on informal physician survey	0.86	0.80	SGD 11,459	SGD 14,344/QALY
REACH3 BAT distribution	0.86	0.80	SGD 29,764	SGD 37,259/QALY
Include concomitant medicines	0.86	0.80	SGD 535	SGD 670/QALY
Include terminal care costs	0.86	0.80	SGD 666	SGD 833/QALY
Drug costs only	0.86	0.80	SGD 11,229	SGD 14,057/QALY

BAT, best available therapy; DoR, duration of response; DoT, duration of treatment; ECP, extracorporeal photopheresis; Gen pop, general population; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; KM, Kaplan–Meier; LY, life year; MMF, mycophenolate mofetil; MTX, methotrexate; OS, overall survival; QALY, quality-adjusted life year; SGD, Singapore dollar

ISSN: 1478-7547